Pancreatic cancer has long ranked among the most unforgiving diagnoses in oncology. Patients often learn of their disease only after it has spread. Median survival in the metastatic setting hovers below a year. Standard chemotherapy brings modest extensions of life at the cost of significant toxicity. Against that backdrop, results from a 500-patient phase 3 trial landed with force at the American Society of Clinical Oncology meeting in Chicago on May 31.
The oral drug daraxonrasib, developed by Revolution Medicines, produced a median overall survival of 13.2 months. Patients assigned to investigator’s choice of second-line chemotherapy lived a median of 6.7 months. The hazard ratio for death stood at 0.40. Statistical significance crossed well beyond the conventional threshold. Progression-free survival showed a similar pattern. Tumors stayed under control for 7.2 months on the pill versus 3.6 months on chemotherapy. These figures held across patients with RAS G12 mutations, who made up more than 90 percent of the study population, and in the broader intent-to-treat group.
The New England Journal of Medicine published the full analysis simultaneously with the presentation. Lead authors Eileen M. O’Reilly of Memorial Sloan Kettering Cancer Center and Brian M. Wolpin of Dana-Farber Cancer Institute oversaw the global effort known as RASolute 302. Their data confirmed what earlier phase 1/2 work had hinted at. In previously treated patients, the targeted RAS(ON) multi-selective inhibitor delivered consistent tumor control. Objective response rates reached roughly 32 percent on daraxonrasib compared with 11 percent on chemotherapy.
But survival numbers alone do not capture the full picture. Quality of life improved enough for some participants to reclaim activities they had set aside. One 74-year-old Texan named Menta “Steve” Wallace resumed travel plans and talked about a cruise after his tumor shrank 46 percent. He had experienced manageable nausea, diarrhea and rash at the start. Weeks later he reported feeling well. Reuters captured his story days before the ASCO presentation, illustrating a practical difference that trial endpoints sometimes obscure.
Side effects occurred. Rash affected 86 percent of patients taking daraxonrasib. Grade 3 or higher adverse events appeared in 44 percent of that arm versus 58 percent in the chemotherapy arm. Mouth inflammation, nausea and diarrhea were common but rarely led to discontinuation. Only 1.2 percent of patients stopped the pill because of treatment-related problems. That figure reached 11 percent among those receiving intravenous chemotherapy. The difference matters in a disease where patients already carry heavy symptom burdens.
Rachna Shroff, chief of oncology at the University of Arizona Cancer Center, had treated pancreatic cancer for 16 years before she read the data. She cried. “It ticks all of the boxes,” she told Reuters. Wolpin, who presented the plenary session results, put it more broadly. “These results will change how scientists, clinicians, and patients think about treatment for pancreatic cancer.” Julie Gralow, ASCO’s chief medical officer, called the outcome a grand slam. The Guardian quoted several advocacy leaders who described the findings as among the most significant developments in decades for a cancer that kills more than half its patients within three months of diagnosis.
The drug’s mechanism explains part of the excitement. Daraxonrasib targets the active, GTP-bound form of RAS proteins. Mutations in RAS genes, particularly KRAS G12 variants, drive up to 90 percent of pancreatic ductal adenocarcinomas. For years researchers viewed the protein as undruggable because its smooth surface offered few places for small molecules to bind. Advances in covalent inhibitors and then non-covalent approaches changed that calculation. Revolution Medicines designed daraxonrasib as a multi-selective RAS(ON) inhibitor capable of shutting down both mutant and wild-type forms. Activity appeared even in patients without confirmed G12 mutations, hinting at broader potential.
Earlier data supported the phase 3 gamble. A phase 1/2 trial published in the New England Journal of Medicine on May 6 showed objective responses in 35 percent of second-line RAS G12 patients at the 300-milligram daily dose selected for further study. Median progression-free survival reached 8.5 months and overall survival 13.1 months in that smaller cohort. Disease control exceeded 90 percent. Those single-arm results, generated across Dana-Farber and other centers, justified launching RASolute 302 against an active chemotherapy comparator rather than placebo.
Analysts and clinicians quickly connected the dots to other tumor types. Similar RAS mutations appear in subsets of lung, colorectal and ovarian cancers. Revolution Medicines has already begun testing daraxonrasib earlier in the pancreatic cancer course and in combinations. Chief executive Mark Goldsmith signaled plans to push survival numbers higher still. The Food and Drug Administration granted fast-track designation. Expanded access programs opened for certain patients while regulators review the data.
Yet caution persists. Pancreatic cancer remains a tough adversary. Thirteen months is progress, not victory. Half the patients in the trial still died within roughly a year. Resistance mechanisms will emerge. Cost, testing logistics and equitable access pose real questions. Tumor genotyping must happen quickly enough for patients to benefit before performance status declines. Health systems in the UK and elsewhere will weigh the months gained against the price of a daily oral therapy taken by thousands.
And. The standing ovation that greeted the plenary presentation reflected more than polite applause. Oncologists rarely witness historic moments in this disease. This one felt different. Decades of near-misses and incremental gains gave way to a statistically robust, clinically meaningful advance delivered in pill form with a tolerable safety profile.
Recent coverage reinforced the sentiment. NBC News reported on May 31 that enthusiasm has reached a fever pitch and noted the drug’s potential reach beyond KRAS-mutant tumors. STAT News quoted pancreatic cancer specialist Rachna Shroff calling the outcome incredibly impactful for patients. The Pancreatic Cancer Action Network and other advocacy groups echoed calls for rapid availability. No single article captured every nuance. Together they paint a consistent portrait of a therapy that shifts expectations.
Investigators continue to mine the data for subgroups that benefit most. They examine duration of response, which stretched beyond eight months in early testing. Biomarker analyses may identify predictors of exceptional outcomes. Combination strategies with chemotherapy or other targeted agents could move the survival curve further. For now the message from Chicago is straightforward. A once-daily pill that targets the dominant driver mutation in pancreatic cancer has doubled survival in the second-line setting while improving how patients feel. That combination has not been seen before.
Steve Wallace’s experience, however anecdotal, lingers. Diagnosed in January, on treatment by mid-February, reporting tumor shrinkage and renewed plans by late spring. His wife Jo Linda stood beside him in photographs published by Reuters. Their story puts numbers into human scale. Months matter when baseline prognosis is measured in weeks.
Pancreatic cancer statistics have improved only modestly over the past generation. Five-year survival for all stages sits near 13 percent. Metastatic disease still carries the heaviest burden. Against that reality, the RASolute 302 trial offers a concrete step forward. It validates years of investment in RAS biology. It gives clinicians a new tool. Most of all it gives patients and families additional time measured not just in quantity but in quality they can use.
The field will not rest here. But on May 31, in a large hall in Chicago, the data were clear. Daraxonrasib changed the conversation about what is possible in advanced pancreatic cancer. The months added today may pave the way for years gained tomorrow.
WebProNews is an iEntry Publication